{"id":4094,"date":"2026-11-04T09:00:00","date_gmt":"2026-11-04T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4094"},"modified":"2026-11-05T20:35:25","modified_gmt":"2026-11-06T00:35:25","slug":"fda-accepts-resubmitted-camrelizumab-rivoceranib-applications","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4094","title":{"rendered":"FDA Accepts Resubmitted Camrelizumab Rivoceranib Applications"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Jiangsu Hengrui; Elevar Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

FDA acceptance of resubmission<\/p>\n

Modality<\/strong><\/p>\n

Anti-PD-1 antibody plus oral TKI<\/p>\n

Asset<\/strong><\/p>\n

Camrelizumab plus rivoceranib<\/p>\n

Target<\/strong><\/p>\n

PD-1; VEGFR2<\/p>\n

Disease Area<\/strong><\/p>\n

Unresectable or metastatic hepatocellular carcinoma<\/p>\n

Summary<\/h4>\n

Previously missed November 4 regulatory update, corroborated by a November 5 Chinese exchange disclosure: FDA accepted the resubmitted camrelizumab biologics application and partner Elevar\u2019s rivoceranib application for first-line unresectable or metastatic hepatocellular carcinoma. The new PDUFA target date is April 9, 2027. Acceptance is a review milestone, not approval.<\/p>\n

Elevar says both applications were resubmitted October 9 after a July 2026 complete response letter. The July action concerned cGMP deficiencies at a manufacturing site associated with rivoceranib. Hengrui\u2019s exchange filing confirms the BLA acceptance and target date. The 543-patient international randomized CARES-310 trial compared camrelizumab plus rivoceranib with sorafenib; published final analysis reported median overall survival of 23.8 versus 15.2 months, with hazard ratio 0.64.<\/p>\n

Deep Analysis<\/h4>\n

Interpretation A:<\/strong> the new review cycle may allow a clinically active China-origin regimen to enter the US HCC market if manufacturing deficiencies are adequately corrected. Randomized survival evidence and an integrated resubmission support that possibility. Counterargument: acceptance does not mean facility remediation has passed inspection, and the prior complete response letter makes CMC execution central.<\/p>\n

Interpretation B:<\/strong> the near-term signal is primarily regulatory process progress, with approval probability still uncertain. The disclosed cGMP history supports caution, while the new target date indicates the filing is sufficiently complete for review. FDA inspection outcome, quality-system remediation, labeling and any additional information requests will discriminate.<\/p>\n

Company and Product Background<\/h4>\n

Hengrui Pharma developed camrelizumab, an anti-PD-1 antibody that blocks inhibitory T-cell signaling. Elevar develops rivoceranib, an oral VEGFR2 tyrosine-kinase inhibitor that targets tumor angiogenesis. The combination is being reviewed for advanced hepatocellular carcinoma in patients without prior systemic therapy.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The original partner announcement was November 4; Hengrui\u2019s Chinese filing was dated November 4 and posted November 5 on the Shanghai Stock Exchange.<\/li>\n
  • This is an FDA review action, not a new clinical readout.<\/li>\n
  • The July complete response letter concerned manufacturing and, according to Hengrui, did not raise clinical efficacy or safety concerns; the FDA\u2019s full current assessment is not public.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The combination has substantial randomized survival evidence, but the next value inflection is a documented manufacturing resolution. No approval inference follows from resubmission acceptance alone.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: positive for regulatory progress; uncertain for approvability. Confidence in Facts: high for matching issuer and exchange disclosures and the peer-reviewed trial. Confidence in Interpretation: moderate-low given unresolved inspection outcome.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Previously missed November 4 regulatory update, corroborated by a November 5 Chinese exchange disclosure: FDA accepted the resubmitted camrelizumab biologics application and partner Elevar\u2019s rivoceranib application for first-line unresectable or metastatic hepatocellular carcinoma. The…<\/p>\n","protected":false},"author":1,"featured_media":4108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[172,1291,173],"class_list":["post-4094","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-elevar-therapeutics","tag-hengrui","tag-hepatocellular-carcinoma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4094"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4094\/revisions"}],"predecessor-version":[{"id":4116,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4094\/revisions\/4116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4108"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}